InvestSMART

Mesoblast Limited (ASX: MSB) - Announcements

Current share price for MSB : $1.785 0.01 (0.56%)+

ASX company news and announcements for Mesoblast Limited (MSB) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Mesoblast Limited (MSB) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Mesoblast Limited (MSB), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Mesoblast Limited (MSB)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$2,323 Positive EMA Meeting For Phase 3 Disc Repair Program 8 Apr 2015 9:57AM $3.280 $1.785 fallen by 45.58%
$2,323 Key Patent Allowed In Japan For Heart Diseases, Stroke 27 Mar 2015 9:45AM $3.580 $1.785 fallen by 50.14%
$2,323 Fast Track Access To Potential Japan Investment Incentives 19 Mar 2015 9:59AM $3.870 $1.785 fallen by 53.88%
$2,323 Results Show Improved Survival in Children with GVHD 16 Feb 2015 9:39AM $4.160 $1.785 fallen by 57.09%
$2,323 Half Yearly Report and Accounts 12 Feb 2015 9:16AM $4.410 $1.785 fallen by 59.52%
$2,323 Key US patent granted for treatment of degenerated discs 10 Feb 2015 10:00AM $4.310 $1.785 fallen by 58.58%
$2,323 Appendix 4C - quarterly 30 Jan 2015 4:50PM n/a $1.785 n/a
$2,323 P3 trial initiated, positive 24 mth P2 results in back pain 15 Jan 2015 8:56AM $4.010 $1.785 fallen by 55.49%
$2,323 Key Mesoblast Patent Claims Upheld in Europe 16 Dec 2014 9:42AM $4.180 $1.785 fallen by 57.30%
$2,323 Chronic Low Back Pain Results Presented at NASS 13 Nov 2014 9:38AM $4.040 $1.785 fallen by 55.82%
$2,323 Appendix 4C - quarterly 31 Oct 2014 3:21PM $4.200 $1.785 fallen by 57.50%
$2,323 MSB PARTNER JCR FILES FOR PRODUCT APPROVAL 1 Oct 2014 9:57AM $4.350 $1.785 fallen by 58.97%
$2,323 MSB Unveils Path to Bring its Key Products to Market 26 Aug 2014 8:58AM $4.520 $1.785 fallen by 60.51%
$2,323 Preliminary Final Report 26 Aug 2014 8:48AM $4.520 $1.785 fallen by 60.51%
$2,323 MSB & NIH Agree 120 Patient Trial In End-Stage Heart Failure 7 Aug 2014 10:17AM $4.020 $1.785 fallen by 55.60%
$2,323 Appendix 4C - quarterly 31 Jul 2014 6:00PM $4.270 $1.785 fallen by 58.20%
$2,323 Circulation Publishes Improved Outcomes with Mesoblast Cells 25 Jun 2014 10:05AM $4.360 $1.785 fallen by 59.06%
$2,323 Mesoblast Receives $5.05m for Stem Cell Pipeline Development 16 Jun 2014 10:19AM $4.330 $1.785 fallen by 58.78%
$2,323 Response to ASX Price Query 6 Jun 2014 9:22AM $4.510 $1.785 fallen by 60.42%
$2,323 MSB Accelerates Plans for Commercial Manufacturing Operation 28 May 2014 12:00PM $4.820 $1.785 fallen by 62.97%
$2,323 Appendix 4C - quarterly 30 Apr 2014 6:21PM $4.660 $1.785 fallen by 61.70%
$2,323 MESOBLAST PROVIDES UPDATE ON CLINICAL PROGRAMS OF PROCHYMAL 29 Apr 2014 10:29AM $4.670 $1.785 fallen by 61.78%
$2,323 Response to ASX price query 8 Apr 2014 9:56AM $4.960 $1.785 fallen by 64.01%
$2,323 Half Yearly Report and Accounts 26 Feb 2014 8:27AM $5.970 $1.785 fallen by 70.10%
$2,323 Key European Patent Granted for Mesoblast's MPCs 20 Feb 2014 9:37AM $5.790 $1.785 fallen by 69.17%

976 - 1000 of 1198 results

Page 40 of 48

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.